1. Home
  2. LUNG vs INGN Comparison

LUNG vs INGN Comparison

Compare LUNG & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LUNG
  • INGN
  • Stock Information
  • Founded
  • LUNG 1995
  • INGN 2001
  • Country
  • LUNG United States
  • INGN United States
  • Employees
  • LUNG N/A
  • INGN N/A
  • Industry
  • LUNG Industrial Specialties
  • INGN Industrial Specialties
  • Sector
  • LUNG Health Care
  • INGN Health Care
  • Exchange
  • LUNG Nasdaq
  • INGN Nasdaq
  • Market Cap
  • LUNG 124.0M
  • INGN N/A
  • IPO Year
  • LUNG 2020
  • INGN 2014
  • Fundamental
  • Price
  • LUNG $2.87
  • INGN $7.05
  • Analyst Decision
  • LUNG Buy
  • INGN Strong Buy
  • Analyst Count
  • LUNG 6
  • INGN 3
  • Target Price
  • LUNG $11.53
  • INGN $11.00
  • AVG Volume (30 Days)
  • LUNG 317.8K
  • INGN 201.5K
  • Earning Date
  • LUNG 07-30-2025
  • INGN 08-05-2025
  • Dividend Yield
  • LUNG N/A
  • INGN N/A
  • EPS Growth
  • LUNG N/A
  • INGN N/A
  • EPS
  • LUNG N/A
  • INGN N/A
  • Revenue
  • LUNG $87,473,000.00
  • INGN $339,960,000.00
  • Revenue This Year
  • LUNG $18.02
  • INGN $7.46
  • Revenue Next Year
  • LUNG $18.17
  • INGN $6.03
  • P/E Ratio
  • LUNG N/A
  • INGN N/A
  • Revenue Growth
  • LUNG 19.84
  • INGN 5.73
  • 52 Week Low
  • LUNG $2.50
  • INGN $5.70
  • 52 Week High
  • LUNG $9.37
  • INGN $13.33
  • Technical
  • Relative Strength Index (RSI)
  • LUNG 39.07
  • INGN 59.08
  • Support Level
  • LUNG $2.62
  • INGN $7.20
  • Resistance Level
  • LUNG $2.88
  • INGN $7.59
  • Average True Range (ATR)
  • LUNG 0.17
  • INGN 0.31
  • MACD
  • LUNG 0.05
  • INGN 0.04
  • Stochastic Oscillator
  • LUNG 39.68
  • INGN 71.70

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: